Who should use it?

We believe that every woman considering IVF procedure can benefit from the personalised treatment plan that beREADY offers. It should always be done before valuable embryo(s) are transferred. The test is designed for all women, whether using their own or donated embryos. And suits for both type of cycle- Hormone Replacement Therapy (HRT) or natural cycle. 

Avoiding the issues caused by the displaced Window Of Implantation (WOI) with personalised IVF plan gives you a higher chance of getting pregnant with fewer attempts, saving you time and resources. Personalised approach is beneficial in all cases, not only if you have limited number of embryos or you have had multiple failed attempts.

Saves women and embryos

Transferring an embryo at the optimal time increases the chances of becoming pregnant.

Saves time

Results in 14 business days. Embryo transfer can be performed in the following cycle.


Applied receptivity biomarkers and technology are based on published research.


Best price and quality ratio.

No need to wish you “good luck” with IFV treatment.


Just apply the personalized medicine test and be READY!

Read what doctors say about beREADY test?

What does the test show?

The beREADY test measures maturity level of your endometrium for successful embryo implantation. The test results are reported in three main categories.The endometrium may be:

1. RECEPTIVE (optimal readiness for embryo transfer)

2. PRE-RECEPTIVE (the tissue needs extra time to mature)

3. POST-RECEPTIVE (receptive period is over)

Based on the results, practical recommendations are provided for your doctor. More specifically, the detected receptivity is expressed as a score on the receptometer. A few samples of possible scenarios:

The sample is pre-receptive. It is not perfect time for day 5 embryo transferring. We recommend to repeat the test 24 hours later in the next cycle.

The new test is highly recommended to confirm that your optimal WOI is achieved.

The sample is receptive (early-receptive) but the optimal WOI is achieved in 12-24 h.

No need to repeat the test. We recommend to transfer the embryo 12-24 hours later.

The sample is receptive. It is the perfect time for day 5 embryo transferring during the next cycle.

No changes are needed in your treatment plan.

The sample is receptive (late-receptive) but endometrial tissue maturation has been quicker and there is a risk that embryo implantation won’t take place.

No need to repeat the test. We recommend to transfer the embryo 12 hours earlier.

If the beREADY test shows that your WOI is significantly shifted, your doctor should change the timing of embryo transfer or drug treatment accordingly.

How does it work for you?

Endometrial sampling is taken one cycle before planned embryo transferring. Your Hormone Replacement Therapy (HRT) scheme should be the same as it will be in the month of your IVF embryo transfer. The sample should be taken on the day when your day 5 embryo transfer should take place in the following month.

It is like a simulation for gaining confidence and finding out the perfect timing for your embryo transfer.

Your doctor is responsible for informing you about the benefits and outcome of the test and making the necessary changes in your treatment plan. You will sign the Patient Informed Consent Form before your sample is taken.

An endometrial tissue sample is preserved in a special solution and analysed in beREADY laboratory. beREADY samples are shipped anonymously – your sample is coded and no documents with personal data are attached to the shipping parcel.

The analysis begins once the sample has arrived to the laboratory. The testing is based on gene expression biomarker profiling, which reflects the readiness of the endometrium. RNA material is extracted from the tissue sample and 67 informative biomarker genes are analysed.

The beREADY test results are sent to your doctor within 14 business days after receiving the sample. The report shows your endometrium’s receptivity level and indicates if any changes are needed in your IVF plan.

Based on the results of your test, the necessary changes could be applied in your next IVF cycle(s). If beREADY report shows that your WOI is significantly shifted and re-sampling is recommended, the analysis of the second sample is free-of-charge. The re-sampling is highly recommended to make sure that the receptiveness of endometrium is achieved with adjustments. It gives you the confidence of knowing that your embryo transfer is planned at the most optimal time, which will increase your chance of successful pregnancy.

beREADY is carefully validated in clinics

The beREADY test has been validated under clinical conditions in two independent international IVF clinics to demonstrate the test’s accuracy. In total, 45 HRT patients’ samples were involved in a comparison against the leading endometrial receptivity test on the market. The concordance rate between two tests was 96 percent.

The small difference is due to the difference in testing methods. The beREADY applies a highly accurate TAC-seq DNA sequencing technology that enables us to detect bio-marker molecules at a single molecule level, providing us with the ultimate accuracy.

Technology behind beREADY

The beREADY test detects 67 biomarker genes that indicate a receptive endometrium. The genes are detected by patent pending and published TAC-seq methodology that applies advanced Illumina DNA sequencing technology. The applied methodology makes endometrium biomarker profiling extremely accurate, detecting the key molecules at a single-molecule level. Extracted biomarker molecules from your sample are tagged by unique DNA barcode, which makes it possible to count the molecule copies at original level even after laboratory manipulations like sample preparation for analysis. TAC-seq technology detects even the slightest of changes in your sample, revealing all progress of endometrial maturation.

Original research behind beREADY test

Saare et al., A molecular tool for menstrual cycle phase dating in endometriosis transcriptomic studies. 2019, Biology of Reproduction, PubMed ID 31004479. Link to original study

Teder et al., TAC-seq: targeted DNA and RNA sequencing for precise biomarker molecule counting. 2018, npj Genomic Medicine, PubMed ID 30588329. Link to original study

Suhorutshenko et al., Endometrial receptivity revisited: endometrial transcriptome adjusted for tissue cellular heterogeneity. 2018, Human Reproduction, PubMed ID 30295736. Link to original study

Altmäe et al., Meta-signature of human endometrial receptivity: a meta-analysis and validation study of transcriptomic biomarkers. 2017, Scientific Reports, PubMed ID 28855728. Link to original study

Krjutškov et al., Single-cell transcriptome analysis of endometrial tissue. 2016, Human Reproduction, PubMed ID 26874359. Link to original study